Research To Practice | Oncology Videos Colorectal Cancer — Proceedings from a Multitumor Symposium in Partnership with Florida Cancer Specialists & Research Institute
Nov 12, 2025
In this intriguing discussion, Dr. Chris Liu, an expert in colorectal cancer and immunotherapy, shares cutting-edge insights on neoadjuvant immune checkpoint inhibitors and their impressive results in MSI-high rectal cancer. He delves into the significance of recent trials, revealing high clinical response rates. Dr. John Strickler, a specialist in biomarker strategies, explores the role of minimal residual disease and the impact of targeted therapies like BRAF and KRAS. Both guests highlight the evolving landscape of colorectal cancer treatment and the importance of personalized approaches.
AI Snips
Chapters
Transcript
Episode notes
Neoadjuvant IO Can Spare Rectal Surgery
- Neoadjuvant immune checkpoint inhibitors produce very high clinical complete response rates in locally advanced MSI-high rectal cancer.
- Chris Liu and trials like dostarlimab suggest neoadjuvant IO can enable non-operative management for many patients.
Brief Dual IO Drives Deep Pathologic Responses
- Short-course neoadjuvant dual checkpoint (nivolumab+ipilimumab) produced very high major and complete pathologic responses in MSI-high colon cancer.
- NICHE2 reported 95% major pathologic response and 100% three-year DFS in that cohort.
Offer Folfox Plus Atezolizumab Post-Resection
- For resected stage III MSI-high colon cancer, offer adjuvant chemotherapy combined with atezolizumab per ATOMIC results.
- If patients present post-resection, recommend Folfox followed by atezolizumab as the current evidence-based option.